Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s primary clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, which is in the pivotal Phase 3 VIITAL clinical trial. Co. is developing additional adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that Co. has licensed from University of North Carolina at Chapel Hill, and internal AAV vector research programs. The ABEO stock yearly return is shown above.
The yearly return on the ABEO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ABEO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|